Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone

Pol Arch Intern Med. 2024 May 28;134(5):16749. doi: 10.20452/pamw.16749. Epub 2024 May 14.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Dexamethasone* / administration & dosage
  • Dexamethasone* / therapeutic use
  • Female
  • Humans
  • Lenalidomide* / therapeutic use
  • Male
  • Middle Aged
  • Multiple Myeloma* / drug therapy
  • Oligopeptides* / therapeutic use
  • Quality of Life*
  • Thalidomide / therapeutic use

Substances

  • Lenalidomide
  • Dexamethasone
  • carfilzomib
  • Oligopeptides
  • Thalidomide

Associated data

  • ClinicalTrials.gov/NCT02659293